BiotechTube

Patisiran + Vutrisiran

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Amyloidosis, Hereditary

Conditions

Amyloidosis, Hereditary, Transthyretin Amyloidosis

Trial Timeline

Feb 14, 2019 → Nov 5, 2025

NCT ID
NCT03759379

About Patisiran + Vutrisiran

Patisiran + Vutrisiran is a phase 3 stage product being developed by Alnylam Pharmaceuticals for Amyloidosis, Hereditary. The current trial status is completed. This product is registered under clinical trial identifier NCT03759379. Target conditions include Amyloidosis, Hereditary, Transthyretin Amyloidosis.

What happened to similar drugs?

0 of 11 similar drugs in Amyloidosis, Hereditary were approved

Approved (0) Terminated (2) Active (9)
🔄NTLA-2001 + PlaceboRegeneron PharmaceuticalsPhase 3
🔄PatisiranAlnylam PharmaceuticalsPhase 3
🔄PatisiranAlnylam PharmaceuticalsPhase 3
🔄Nucresiran + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 3
🔄Vutrisiran + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 3
🔄Placebo + PatisiranAlnylam PharmaceuticalsPhase 3
🔄patisiran (ALN-TTR02) + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03759379Phase 3Completed

Competing Products

20 competing products in Amyloidosis, Hereditary

See all competitors
ProductCompanyStageHype Score
ZN-d5Zentalis PharmaceuticalsPhase 1/2
22
VELCADEJohnson & JohnsonPhase 1/2
32
ABBV-383 (Etentamig)AbbViePhase 1/2
39
Venetoclax + Dexamethasone + DaratumumabAbbViePhase 1/2
24
Eplontersen Solution for InjectionAstraZenecaPhase 1
29
Treatment of transthyretin (ATTR) amyloidosis in observational study settingAstraZenecaPre-clinical
33
Carfilzomib + DexamethasoneAmgenPhase 1
29
IdelalisibGilead SciencesPhase 2
27
TafamidisPfizerPre-clinical
26
TafamidisPfizerPre-clinical
30
Fx-1006APfizerPhase 2
35
tafamidisPfizerPre-clinical
26
Cyclophosphamide + Dexamethasone + Elotuzumab + LenalidomideBristol Myers SquibbPhase 2
31
IsatuximabBristol Myers SquibbPhase 2
42
Bortezomib + Cyclophosphamide + Dexamethasone + IsatuximabSanofiPhase 1
33
Bendamustine Hydrochloride + IsatuximabSanofiPhase 2
27
NC-503 (Anti-amyloidotic (AA) Agent)GSK plcPhase 2/3
38
NTLA-2001 + PlaceboRegeneron PharmaceuticalsPhase 3
44
LinvoseltamabRegeneron PharmaceuticalsPhase 1/2
39
ALN-TTR01 + Sterile Normal Saline (0.9% NaCl)Alnylam PharmaceuticalsPhase 1
26